Crescent at Chevy Chase

About Crescent at Chevy Chase

Cushman & Wakefield’s Mid-Atlantic Multifamily Advisory Group is pleased to present Crescent at Chevy Chase, a newly constructed asset located in Chevy Chase, Maryland, one of the wealthiest suburbs in the broader DC metro area. The Property is located squarely in the path of growth, as it is just a 5-minute walk to the Connecticut Avenue Purple Line stop, which is currently under construction and will be delivered in December 2027, providing transit access from New Carrollton to downtown Bethesda. This transit expansion will provide easy access to the haven of amenities in downtown Bethesda, which has over 1.7M SF of retail space and is the home of numerous Fortune 500 companies. The property’s location also allows for easy access to I-495 and I-270, providing access to the bulk of suburban Maryland’s prominent federal and regional employers, including the NIH, Marriott International Headquarters, Walter Reed National Medical Center, Suburban Hospital, Lockheed Martin, and the broader I-270 Biotechnology Corridor which is the pre-eminent research corridor in the country with over 300 biotech companies and more than 50,000 employees. The demographics within a one-mile radius of the property are among the best in the region, as median household income, bachelor’s degree attainment, and white-collar employment all exceed those of Montgomery County and the Washington DC MSA. On top of this, the average monthly mortgage payment needed for the median home sale price in Chevy Chase is 146% higher than the average effective rent in the Chevy Chase submarket, further driving foot traffic to rental housing. The property was constructed to LEED certification standards, resulting in a full county tax abatement through 2028, boosting the property’s appeal and value for future ownership. Crescent at Chevy Chase is an ideal opportunity to acquire a best-in-class asset in a dynamic location with rental and operational upside potential, at an attractive discount to replacement cost.